Ostatní
Návod 
Sangamo Therapeutics, Inc.
SGMO
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.1B
Obrat
0B
Zisk
0B
Aktiva
0B
Dluh
0B
ROE
-1744%
ROA
-123%
PE
-1
PS
3
Cena 1R
0-1
⌀ Cena
0.55
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
16-03-2026
Poslední dividenda
Profil
Společnost Sangamo Therapeutics, Inc., která působí v klinickém stádiu biotechnologie, se zaměřuje na přeměnu vědy v genomická léčiva, která transformují životy pacientů pomocí platformních technologií v oblasti genové terapie, buněčné terapie, editace genomu a regulace genomu. Společnost nabízí zinek finger protein (ZFP), technologickou platformu pro výrobu zinkových prstových nukleáz, což jsou bílkoviny používané při modifikaci sekvencí DNA přidáním nebo vyřazením specifických genů; a ZFP transkripční faktory proteiny používané při zvyšování nebo snižování genové exprese. Vyvíjí SB-525, který je ve fázi III klinické studie AFFINE pro léčbu hemofilie A; ST-920, genovou terapii, která je ve fázi I/II klinických studií STAAR pro léčbu Fabryho choroby; a SAR445136, buněčnou terapii, která je ve fázi I/II PRECIZN-1 klinických studií pro léčbu srpkovité buňky. Společnost také vyvíjí TX200, chimerický antigenní receptor pro léčbu rejekce transplantovaného orgánu HLA-A2, KITE-037, buněčnou terapii pro léčbu rakoviny, ST-501 pro léčbu tauopatií a ST-502 pro léčbu synukleinopatií, včetně Parkinsonovy choroby a neuromuskulárního onemocnění. Spolupracuje a strategicky spolupracuje se společnostmi Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd a Hoffmann-La Roche Inc.; a California Institute for Regenerative Medicine. Společnost byla dříve známá jako Sangamo BioSciences, Inc. a v lednu 2017 změnila svůj název na Sangamo Therapeutics, Inc. Společnost Sangamo Therapeutics, Inc. byla založena v roce 1995 a sídlí v Brisbane v Kalifornii.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
183
Založení
2000-04-06
Podobné společnosti
$ 2.30
- $ 0.04
$ 1.45
+ $ 0.07
$ 1.68
- $ 0.02
$ 6.35
+ $ 0.57
$ 1.96
- $ 0.06
$ 2.29
+ $ 0.51
$ 4.24
- $ 0.50
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 39.6 | 39.6 | 57.8 | 176.2 | 111.3 | 110.7 | 118.2 | 102.4 | 84.5 | 36.6 | 19.4 | 39.5 | 45.9 | 24.1 | 21.7 | 10.3 | 20.8 | |
| Cost of Revenues | 0.0 | 0.0 | 0.0 | 221.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Gross Profit | 25.3 | 0.0 | 57.8 | -45.3 | 111.3 | 110.7 | 118.2 | 102.4 | 84.5 | 36.6 | 19.4 | 39.5 | 45.9 | 24.1 | 21.7 | 10.3 | 20.8 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 14.2 | 0.6 | 18.3 | 6.4 | 7.6 | 49.4 | 0.4 | 0.5 | 2.0 | 9.4 | |
| Cost of Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.0 | 9.5 | |
| Gross Profit | 0.0 | 0.6 | 18.3 | 6.4 | 7.6 | 49.4 | 0.4 | 0.5 | -0.9 | -0.1 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 234.1 | 249.9 | 230.8 | 180.6 | 145.9 | 114.9 | 65.7 | 65.6 | 67.2 | 56.7 | 37.0 | 31.7 | 32.1 | 33.2 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 61.2 | 62.7 | 63.2 | 67.1 | 61.7 | 46.7 | 27.2 | 26.3 | 19.2 | 15.7 | 13.8 | 12.1 | 14.0 | 12.6 | |
| Depreciation & Amortization | 5.7 | 0.0 | 9.4 | 22.2 | 20.6 | 17.6 | 13.4 | 9.6 | 2.4 | 1.5 | 1.0 | 1.0 | 0.5 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Total Operating Expenses | 160.8 | 160.8 | 161.8 | 450.2 | 312.6 | 294.0 | 247.7 | 207.6 | 161.6 | 92.9 | 91.9 | 86.4 | 72.4 | 50.8 | 43.9 | 46.1 | 45.7 | |
| Operating Income | -121.2 | -121.2 | -104.0 | -274.0 | -201.3 | -183.3 | -129.6 | -105.2 | -77.2 | -56.4 | -72.6 | -46.9 | -26.8 | -26.7 | -22.2 | -35.8 | -24.9 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 51.2 | 57.1 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.2 | 13.9 | ||
| Depreciation & Amortization | 0.0 | 1.9 | 1.9 | 1.9 | 2.1 | 2.1 | 2.6 | 2.5 | 3.0 | 9.5 | ||
| Total Operating Expenses | 52.4 | 36.1 | 36.2 | 36.1 | 33.5 | 38.8 | 37.4 | 52.0 | 61.4 | 71.0 | ||
| Operating Income | -38.2 | -35.6 | -17.9 | -29.6 | -26.0 | 10.6 | -37.1 | -51.5 | -62.4 | -106.4 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 1.3 | 1.3 | 5.9 | 11.1 | 9.4 | 5.3 | 8.8 | 0.0 | 8.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | -9.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Expense | -2.3 | -2.3 | 5.9 | 11.1 | 9.4 | 5.3 | 8.8 | 9.8 | 8.3 | 1.8 | 0.9 | 0.4 | -0.2 | -0.1 | -0.1 | 0.1 | 0.1 | |
| IBT | -123.5 | -123.5 | -98.1 | -262.9 | -191.8 | -178.0 | -120.8 | -95.4 | -68.9 | -54.6 | -71.7 | -46.4 | -26.4 | -26.6 | -22.3 | -35.8 | -24.9 | |
| Income Tax Expense | -0.6 | -0.6 | -0.2 | -5.1 | 0.4 | 0.3 | 0.3 | -19.6 | 8.3 | -1.5 | 0.0 | -5.7 | -0.7 | -0.6 | -0.7 | -0.6 | -0.7 | |
| Net Income | -122.9 | -122.9 | -97.9 | -257.8 | -192.3 | -178.3 | -121.1 | -75.8 | -68.3 | -54.6 | -71.7 | -40.7 | -26.4 | -26.6 | -22.3 | -35.8 | -24.9 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 0.3 | 0.4 | 0.4 | 0.3 | 2.2 | 0.1 | 1.0 | 0.5 | 1.5 | 3.5 | ||
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| Other Expense | 0.2 | 0.5 | -2.1 | -0.9 | 2.2 | 0.1 | 1.0 | 2.5 | 1.5 | 3.5 | ||
| IBT | -38.0 | -35.1 | -20.0 | -30.5 | -23.8 | 10.8 | -36.1 | -49.0 | -60.6 | -102.9 | ||
| Income Tax Expense | -0.6 | -0.2 | 0.0 | 0.1 | -0.4 | 0.1 | 0.1 | 0.1 | -0.3 | 1.3 | ||
| Net Income | -37.4 | -34.9 | -20.0 | -30.6 | -23.4 | 10.7 | -36.1 | -49.1 | -60.3 | -104.2 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-1.48 | $-1.25 | $-1.23 | $-0.90 | $-0.68 | $-0.70 | $-0.70 | $-1.02 | $-0.58 | $-0.39 | $-0.48 | $-0.42 | $-0.71 | $-0.55 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-1.48 | $-1.25 | $-1.23 | $-0.90 | $-0.68 | $-0.70 | $-0.70 | $-1.02 | $-0.58 | $-0.39 | $-0.48 | $-0.42 | $-0.71 | $-0.55 | |
| Shares Outstanding | 337.7 | 280.2 | 201.7 | 174.4 | 154.3 | 144.6 | 134.4 | 112.1 | 96.9 | 78.1 | 70.6 | 69.8 | 67.0 | 56.0 | 52.7 | 50.5 | 45.2 | |
| Diluted Shares Outstanding | 337.7 | 280.2 | 201.7 | 174.4 | 154.3 | 144.6 | 134.4 | 112.1 | 96.9 | 78.1 | 70.6 | 69.8 | 67.0 | 56.0 | 52.7 | 50.5 | 45.2 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.34 | $-0.59 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $-0.34 | $-0.59 | ||
| Shares Outstanding | 337.7 | 304.3 | 257.0 | 220.3 | 210.2 | 208.3 | 203.9 | 180.3 | 177.6 | 176.5 | ||
| Diluted Shares Outstanding | 337.7 | 304.3 | 257.0 | 220.3 | 210.2 | 214.3 | 203.9 | 180.3 | 177.6 | 177.2 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 27.8 | 41.9 | 45.2 | 100.4 | 178.9 | 131.3 | 80.4 | 140.4 | 49.8 | 22.1 | 69.5 | 6.0 | 10.2 | 21.7 | 16.8 | 10.8 | |
| Short Term Investments | 108.8 | 0.0 | 35.8 | 177.2 | 197.7 | 510.1 | 282.0 | 259.7 | 193.5 | 120.5 | 139.5 | 172.9 | 82.6 | 41.9 | 67.4 | 49.5 | |
| Total Cash & ST Investments | 27.8 | 41.9 | 81.0 | 277.6 | 464.7 | 692.0 | 385.0 | 400.5 | 244.6 | 142.8 | 209.3 | 226.6 | 131.8 | 76.3 | 84.1 | 60.3 | |
| Accounts Receivable | 0.6 | 4.6 | 1.3 | 4.5 | 6.4 | 6.3 | 37.6 | 5.0 | 3.6 | 5.2 | 2.8 | 10.8 | 3.5 | 4.3 | 1.3 | 0.7 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | -88.2 | -50.5 | -22.5 | -0.4 | -1.3 | -0.2 | -0.3 | -46.7 | -38.2 | -12.5 | 0.0 | 0.0 | |
| Other Current Assets | 11.7 | 5.2 | 12.0 | 18.2 | 15.9 | 12.0 | 5.4 | 5.3 | 1.5 | 1.8 | 0.8 | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | |
| Total Current Assets | 40.1 | 51.7 | 94.3 | 300.3 | 398.8 | 659.7 | 405.5 | 410.5 | 248.4 | 149.6 | 212.6 | 190.9 | 97.3 | 68.4 | 85.7 | 61.3 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 30.5 | 38.3 | 25.2 | 41.9 | 39.2 | 27.8 | 54.4 | 45.2 | 56.5 | 66.8 | |
| Short Term Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 35.8 | 75.6 | 76.3 | |
| Total Cash & ST Investments | 30.5 | 38.3 | 25.2 | 41.9 | 39.2 | 27.8 | 54.4 | 81.0 | 132.1 | 143.1 | |
| Accounts Receivable | 5.1 | 5.0 | 4.6 | 4.6 | 10.5 | 0.6 | 0.7 | 1.3 | 1.8 | 3.9 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 8.4 | 6.6 | 7.8 | 5.2 | 8.4 | 11.7 | 13.5 | 12.0 | 13.7 | 12.6 | |
| Total Current Assets | 44.1 | 49.9 | 37.6 | 51.7 | 58.1 | 40.1 | 68.6 | 94.3 | 147.6 | 159.6 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 39.3 | 34.8 | 52.9 | 125.5 | 124.7 | 112.4 | 107.2 | 78.7 | 31.1 | 6.6 | 2.9 | 1.5 | 1.4 | 1.5 | 1.6 | 1.7 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 37.6 | 39.7 | 42.8 | 39.3 | 40.0 | 1.6 | 1.6 | 0.0 | 1.6 | 1.6 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 50.7 | 53.8 | 58.1 | 53.2 | 54.9 | 0.0 | 0.0 | 1.6 | 1.9 | 1.9 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 0.0 | 1.5 | 0.0 | 29.8 | 88.2 | 50.5 | 21.8 | -6.7 | 1.0 | 0.0 | 0.0 | 47.3 | 38.7 | 12.6 | 0.0 | 0.0 | |
| Other Long-Term Assets | 13.6 | 13.7 | 18.1 | 12.3 | 10.2 | 7.9 | 4.0 | 6.2 | 4.7 | 0.2 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Long-Term Assets | 52.9 | 49.9 | 71.0 | 262.2 | 323.2 | 278.9 | 232.0 | 179.9 | 38.3 | 8.3 | 4.7 | 52.3 | 43.6 | 14.2 | 1.6 | 1.7 | |
| Total Assets | 93.0 | 101.6 | 165.3 | 562.5 | 721.9 | 938.6 | 637.5 | 590.4 | 286.7 | 157.9 | 217.2 | 243.2 | 140.8 | 82.5 | 87.3 | 63.0 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 29.2 | 30.8 | 32.8 | 34.8 | 36.9 | 39.3 | 43.0 | 52.9 | 55.6 | 107.5 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 0.0 | 1.5 | 1.5 | 1.5 | 1.5 | 0.0 | 0.0 | 1.5 | 1.5 | 39.0 | |
| Other Long-Term Assets | 15.3 | 15.4 | 14.2 | 13.7 | 14.7 | 13.6 | 17.4 | 16.6 | 15.0 | 18.9 | |
| Total Long-Term Assets | 44.6 | 47.7 | 48.6 | 49.9 | 53.1 | 52.9 | 60.3 | 71.0 | 72.1 | 165.5 | |
| Total Assets | 88.6 | 97.6 | 86.2 | 101.6 | 111.3 | 93.0 | 129.0 | 165.3 | 219.7 | 325.1 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 17.6 | 15.5 | 15.3 | 22.4 | 9.8 | 12.6 | 6.7 | 3.4 | 0.0 | 2.6 | 3.9 | 5.5 | 3.0 | 3.0 | 4.1 | 0.0 | |
| Short-Term Debt | 0.0 | 4.3 | 4.6 | 4.1 | 4.0 | 3.7 | 3.2 | 0.0 | 0.0 | 0.0 | 0.0 | 6.0 | 4.6 | 1.1 | 0.0 | 0.0 | |
| Other Current Liabilities | 21.4 | 14.4 | 27.9 | 33.4 | 28.4 | 30.7 | 21.3 | 27.6 | 16.5 | 6.6 | 7.1 | 0.3 | 0.3 | 2.3 | 2.9 | 7.0 | |
| Current Liabilities | 39.0 | 45.8 | 47.7 | 111.7 | 127.9 | 143.5 | 69.9 | 78.5 | 44.9 | 13.3 | 20.1 | 20.9 | 10.1 | 8.8 | 7.2 | 7.1 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 15.6 | 10.7 | 18.2 | 15.5 | 19.8 | 17.6 | 15.5 | 15.3 | 15.5 | 14.8 | |
| Short-Term Debt | 0.0 | 0.0 | 0.0 | 4.3 | 0.0 | 0.0 | 0.0 | 4.6 | 0.0 | 0.0 | |
| Other Current Liabilities | 27.0 | 24.8 | 19.6 | 18.5 | 7.9 | 7.8 | 7.4 | 27.9 | 31.5 | 32.1 | |
| Current Liabilities | 50.1 | 47.7 | 49.6 | 45.8 | 43.2 | 39.0 | 40.2 | 47.7 | 48.5 | 53.8 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 29.1 | 26.3 | 33.5 | 39.0 | 44.1 | 38.4 | 41.2 | 27.7 | 24.7 | 3.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Capital Leases | 29.1 | 30.6 | 33.5 | 43.1 | 48.1 | 42.1 | 44.4 | 27.7 | 24.7 | 3.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 6.3 | 6.6 | 7.2 | 6.6 | 6.7 | -24.7 | -3.9 | 0.0 | 0.7 | 0.7 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 69.3 | 78.9 | 82.4 | 267.6 | 346.6 | 441.2 | 204.8 | 223.9 | 98.8 | 21.7 | 24.8 | 36.6 | 19.1 | 17.6 | 7.2 | 7.1 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 25.4 | 23.5 | 24.9 | 26.3 | 27.7 | 29.1 | 30.8 | 33.5 | 35.0 | 36.4 | |
| Capital Leases | 0.0 | 23.5 | 24.9 | 30.6 | 27.7 | 29.1 | 30.8 | 33.5 | 35.0 | 36.4 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 82.4 | 78.0 | 81.3 | 78.9 | 72.1 | 69.3 | 72.3 | 82.4 | 84.8 | 91.4 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 2.1 | 2.1 | 1.8 | 1.7 | 1.5 | 1.4 | 1.2 | 1.0 | 0.9 | 0.7 | 0.7 | 0.7 | 0.6 | 0.5 | 0.5 | 0.5 | |
| Retained Earnings | -1,491.6 | -1,504.3 | -1,406.4 | -1,148.5 | -956.3 | -778.0 | -657.0 | -562.7 | -495.5 | -440.9 | -369.3 | -328.6 | -302.1 | -275.5 | -253.2 | -217.5 | |
| Comprehensive Income | -5.9 | -7.5 | -4.6 | -8.4 | -4.0 | 5.4 | -2.4 | -1.4 | -0.3 | 0.0 | -4.8 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Common Equity | 23.7 | 22.8 | 82.9 | 295.0 | 375.3 | 497.4 | 432.7 | 366.5 | 187.9 | 136.2 | 192.4 | 206.6 | 121.7 | 64.9 | 80.1 | 55.9 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 3.2 | 2.7 | 2.3 | 2.1 | 2.1 | 2.1 | 2.0 | 1.8 | 1.8 | 1.8 | |
| Retained Earnings | -1,589.8 | -1,554.9 | -1,534.9 | -1,504.3 | -1,480.9 | -1,491.6 | -1,455.5 | -1,406.4 | -1,346.1 | -1,241.9 | |
| Comprehensive Income | -1.4 | -1.5 | -5.5 | -7.5 | -4.2 | -5.9 | -5.8 | -4.6 | -6.6 | -5.9 | |
| Total Common Equity | 6.2 | 19.6 | 4.9 | 22.8 | 39.1 | 23.7 | 56.7 | 82.9 | 134.9 | 233.6 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 29.1 | 30.6 | 38.1 | 43.1 | 48.1 | 42.1 | 44.4 | 27.7 | 24.7 | 3.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 23.7 | 22.8 | 82.9 | 295.0 | 375.3 | 497.4 | 432.7 | 366.5 | 187.9 | 136.2 | 192.4 | 206.6 | 121.7 | 64.9 | 80.1 | 55.9 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 6.2 | 19.6 | 4.9 | 22.8 | 39.1 | 23.7 | 56.7 | 82.9 | 134.9 | 233.6 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -249.7 | -122.9 | -97.9 | -257.8 | -192.3 | -178.3 | -121.1 | -95.4 | -68.9 | -54.6 | -71.7 | -40.7 | -26.4 | -26.6 | -22.3 | -35.8 | -24.9 | |
| Depreciation & Amortization | 15.5 | 7.6 | 9.4 | 22.2 | 20.6 | 17.6 | 13.4 | 9.6 | 2.4 | 1.5 | 1.0 | 1.0 | 0.5 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Stock-Based Compensation | 18.1 | 9.1 | 12.4 | 27.4 | 31.7 | 33.0 | 25.7 | 19.3 | 14.7 | 9.1 | 15.1 | 11.7 | 9.2 | 6.1 | 5.3 | 8.1 | 7.8 | |
| Change Working Capital | -8.2 | 0.0 | 4.5 | -164.0 | -82.3 | -101.9 | 252.6 | -73.0 | 93.3 | 55.7 | -10.6 | -0.9 | 9.7 | -0.5 | 7.2 | -0.4 | -8.8 | |
| Change In Accounts Receivable | 2.7 | 0.2 | 1.0 | 3.1 | 2.3 | -0.8 | 31.7 | -32.2 | -1.3 | 1.6 | -2.1 | 7.8 | -7.2 | 1.0 | -3.4 | -0.6 | -0.3 | |
| Change In Accounts Payable | 4.0 | 2.8 | -14.2 | 5.6 | 13.3 | -7.7 | 10.7 | -4.2 | -6.4 | 3.2 | -2.3 | -0.8 | 4.3 | 0.3 | -1.5 | -0.1 | 0.0 | |
| Change In Inventories | -1.2 | 0.0 | 0.0 | 0.0 | 0.0 | 7.7 | -10.7 | 4.2 | -1.0 | -0.7 | -1.0 | 0.5 | -0.3 | 0.0 | 0.2 | -0.1 | 0.0 | |
| Other Non-cash Items | 70.8 | 9.0 | 4.6 | 153.8 | -1.2 | -6.4 | -0.7 | 0.2 | 1.0 | 0.1 | 0.3 | 0.9 | 0.2 | 0.1 | 6.2 | -35.8 | 9.0 | |
| Cash from Operations | -173.4 | 0.0 | 0.0 | -224.8 | -223.6 | -233.3 | 169.9 | -144.4 | 37.2 | 11.2 | -65.9 | -33.7 | -5.7 | -19.5 | -8.1 | -25.9 | -23.9 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -37.4 | -34.9 | -20.0 | -30.6 | -23.4 | 10.7 | -36.1 | -49.1 | -60.3 | -104.2 | |
| Depreciation & Amortization | 1.9 | 1.9 | 1.9 | 1.9 | 2.1 | 2.1 | 2.6 | 2.5 | 3.0 | 7.4 | |
| Stock-Based Compensation | 2.1 | 2.1 | 2.2 | 2.6 | 3.3 | 3.3 | 3.1 | 2.7 | 6.1 | 6.2 | |
| Change Working Capital | -2.5 | 2.4 | -2.3 | -0.1 | 15.3 | -4.5 | 2.5 | -8.9 | 0.8 | -2.7 | |
| Change In Accounts Receivable | 0.2 | -0.2 | 0.0 | 0.2 | 10.1 | -9.9 | 3.0 | -1.2 | 0.4 | 1.6 | |
| Change In Accounts Payable | -1.5 | 4.0 | -3.9 | 4.2 | -7.3 | -2.2 | 0.0 | -4.9 | 10.8 | -2.1 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.3 | 2.1 | |
| Other Non-cash Items | 11.5 | 0.0 | 0.0 | 0.0 | -0.7 | 0.1 | 1.1 | 4.1 | 0.0 | 45.8 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -50.5 | -47.3 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -5.4 | -0.1 | -0.3 | -21.2 | -20.2 | -23.3 | -14.7 | -20.7 | -43.1 | -3.8 | -0.7 | -2.4 | -0.6 | -0.4 | -0.7 | -0.6 | -0.7 | |
| Acquisitions | 93.9 | 0.0 | 2.0 | 0.0 | 0.0 | -0.1 | -0.7 | -0.3 | -75.6 | 0.0 | 0.0 | -2.0 | -1.0 | 0.1 | 0.0 | 0.0 | 0.0 | |
| Investments | -7.4 | 0.0 | 0.0 | -59.6 | -277.4 | -338.2 | -570.8 | -443.7 | -451.2 | -252.3 | -218.6 | -258.0 | -227.8 | -118.9 | -91.4 | -113.0 | -100.0 | |
| Sales of Investment | 124.0 | 0.0 | 35.8 | 234.2 | 356.8 | 609.8 | 314.6 | 404.8 | 391.8 | 178.7 | 237.5 | 337.9 | 127.8 | 51.1 | 103.5 | 93.6 | 113.1 | |
| Other Investing Activities | 116.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.5 | 0.0 | 2.0 | 1.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Cash from Investing | 111.3 | 0.0 | 0.0 | 153.5 | 59.3 | 248.2 | -271.6 | -59.8 | -178.1 | -80.9 | 18.1 | 77.5 | -100.7 | -68.1 | 11.3 | -20.0 | 12.4 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | 0.0 | -0.1 | 0.0 | 0.0 | -0.2 | -0.1 | 0.0 | 0.0 | -2.7 | -2.7 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 134.3 | -40.4 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -7.4 | |
| Sales of Investment | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 35.8 | 40.4 | 47.8 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 40.4 | 40.4 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 37.7 | 37.6 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | -7.3 | 30.6 | -7.5 | -5.0 | -5.0 | 6.0 | -2.3 | 16.7 | 3.0 | 20.8 | 3.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Issuance of Common Stock | 37.4 | 0.0 | 0.0 | 15.1 | 84.9 | 27.1 | 142.5 | 136.3 | 232.0 | 98.1 | 1.1 | 6.8 | 106.7 | 78.1 | 1.7 | 51.9 | 1.2 | |
| Repurchase of Common Stock | -0.4 | 0.3 | 0.0 | 0.0 | 1.8 | 3.4 | 2.0 | 2.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | -0.3 | 0.0 | 0.0 | -0.5 | -2.0 | 2.4 | 8.6 | 3.7 | -0.3 | -0.7 | -0.8 | 12.9 | -4.6 | -2.0 | 0.0 | 0.0 | 0.0 | |
| Cash from Financing | 21.7 | 0.0 | 0.0 | 14.6 | 84.7 | 32.9 | 153.1 | 142.0 | 231.7 | 97.5 | 0.3 | 19.7 | 102.2 | 76.1 | 1.7 | 51.9 | 1.2 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 25.4 | 2.0 | -1.4 | -5.7 | 2.8 | -1.4 | -1.7 | -7.3 | 3.1 | -1.4 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.7 | 0.7 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.4 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | -0.8 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | -0.1 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -39.0 | -22.5 | -3.3 | -55.2 | -78.4 | 47.5 | 50.9 | -62.0 | 90.6 | 27.8 | -47.4 | 63.5 | -4.2 | -11.5 | 4.9 | 6.0 | -10.4 | |
| Closing Cash Balance | 27.8 | 20.9 | 43.4 | 46.7 | 101.9 | 180.4 | 132.8 | 81.9 | 143.9 | 49.8 | 22.1 | 69.5 | 6.0 | 10.2 | 21.7 | 16.8 | 10.8 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -9.6 | -7.8 | 13.2 | -16.7 | 2.7 | 12.9 | -27.5 | 8.6 | -11.3 | -10.3 | |
| Closing Cash Balance | 20.9 | 30.5 | 39.8 | 26.7 | 43.4 | 40.7 | 27.8 | 55.3 | 45.2 | 58.0 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -178.8 | -97.3 | -67.4 | -246.0 | -243.8 | -256.5 | 155.2 | -165.1 | -5.9 | 7.4 | -66.6 | -36.1 | -6.3 | -19.9 | -8.8 | -26.5 | -24.6 | |
| Real Free Cash Flow | -196.9 | -106.4 | -79.8 | -273.4 | -275.4 | -289.5 | 129.5 | -184.4 | -20.6 | -1.7 | -81.7 | -47.9 | -15.5 | -26.1 | -14.1 | -34.6 | -32.4 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -24.4 | -28.6 | -18.2 | -26.1 | -3.5 | 11.6 | -26.9 | -48.7 | -53.2 | -50.0 | |
| Real Free Cash Flow | -26.5 | -30.7 | -20.4 | -28.7 | -6.8 | 8.3 | -29.9 | -51.4 | -59.3 | -56.2 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -0.9 | -14.1 | -1.4 |
| P/S | 2.8 | 16.3 | 9.4 |
| P/B | 17.9 | 4.7 | 5.2 |
| P/FCF | -1 | -18.2 | -1.5 |
| Market cap | $0.1 | $0.4 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 28.7 % | 5.7 % | 0 % |
| Debt to Income | -20.7 % | -15.4 % | 0 % |
| Debt to Free cash flow | -23.9 % | -1295.3 % | 0 % |
| Interest expense percentage | 0 % | -10.7 % | 44.7 % |
| Current ratio | 0.9 | 7.9 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -1969.1 % | -127.6 % | 0 % |
| ROA | -138.7 % | -40.2 % | 0 % |
| CapEx to Revenue | 0.7 % | 12.6 % | 0 % |
| RaD to Revenue | 0 % | 213 % | 0 % |
| ROEM | 216,131.1 | 236830.5 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 100 % | 95.4 % | 68.7 % |
| Operating margin | -331.6 % | -208.4 % | 35.5 % |
| Net margin | -331.3 % | -206.5 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 304.3 mil | 106.7 mil |
| Employee count | 0.2 tis | 0.2 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
